Education
About Us
Working with TipRanks
Follow Us
Quest Diagnostics (DGX)
NYSE:DGX
Earnings Data
Report Date
Apr 28, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
2.37Last Year’s EPS
2.21Same Quarter Last Year
Moderate Buy
Based on 11 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong organic growth, meaningful volume expansion, double-digit full-year revenue and EPS growth, a sizable increase in cash from operations, robust consumer and advanced diagnostics momentum, and clear cost-saving/automation progress. Near-term challenges include margin dilution from new low-margin CoLab ramping and implementation costs, a small decline in revenue-per-requisition driven by large-volume lower-price relationships, weather-related seasonality risk in early 2026, cash-flow comparatives due to one-time items, and unresolved structural/regulatory PAMA risks and some reimbursement uncertainties for new oncology tests. On balance the company presented positive operating and financial momentum with manageable near-term headwinds.Company Guidance
Quarterly Revenue Growth
Consolidated revenues of $2.81B in Q4, up 7.1% year-over-year; consolidated organic revenues grew 6.4%.
Volume Expansion
Total requisitions increased 8.5% versus 2024 (organic volume +7.9%); excluding Corewell and Fresenius organic volume growth accelerated to 4.1%.
Earnings and Profitability Progress
Reported Q4 EPS $2.18 and adjusted EPS $2.42 vs prior year $1.95 and $2.23 (adjusted EPS up ~8.5% year-over-year); reported operating income $386M (13.8% of revenues) and adjusted operating income $429M (15.3%).
Full-Year Financial Achievements
Delivered double-digit growth in full-year revenues and EPS; cash from operations rose to $1.89B for 2025 from $1.33B in 2024 (approximately +42%).
Strong Consumer Channel Performance
Consumer channel delivered nearly $250M in revenue for the full year; direct-to-consumer (questhealth.com) grew strongly (approx. 35% growth for questhealth.com in 2025 and a ~$100M run-rate), and consumer-initiated testing exceeded the >20% growth expectation.
Advanced Diagnostics Momentum
Double-digit revenue growth across advanced diagnostic areas (autoimmune, brain health AD-Detect, oncology MRD, cardiometabolic); launched Analyzer autoimmune solution, 85-biomarker Elite Health Profile, flow MRD test for myeloma and continued AD-Detect adoption.
Operational Efficiency Achieved
INFIGURATE program achieved full-year target of 3% annual cost savings/productivity improvements in 2025; deployed automation and AI (automated sample processing, collaborative accessioning, Hologic system in two labs).
AI and Automation Benefits
Virtual AI agent reduced routine logistics calls by up to 50%; new AI logistics tool expected to reduce courier transportation times as rolled out in 2026.
Positive 2026 Guidance
2026 guidance: revenue $11.70B–$11.82B (growth 6.0%–7.1%); reported EPS $9.45–$9.65; adjusted EPS $10.50–$10.70; cash from operations ~ $1.75B; capex ~$550M; operating margin expected to expand.
Strategic Hospital and CoLab Expansion
CoLab Solutions expected to generate ~ $1B in annual revenue in 2026; Corewell CoLab relationship to add ~ $250M organic revenue in 2026 and a larger joint-lab buildout planned to serve Michigan in 2027.
DGX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DGX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 10, 2026 | $191.25 | $205.35 | +7.37% |
Oct 21, 2025 | $189.54 | $183.80 | -3.03% |
Jul 22, 2025 | $164.96 | $176.65 | +7.08% |
Apr 22, 2025 | $159.69 | $170.52 | +6.78% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Quest Diagnostics (DGX) report earnings?
Quest Diagnostics (DGX) is schdueled to report earning on Apr 28, 2026, Before Open (Confirmed).
What is Quest Diagnostics (DGX) earnings time?
Quest Diagnostics (DGX) earnings time is at Apr 28, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is DGX EPS forecast?
DGX EPS forecast for the fiscal quarter 2026 (Q1) is 2.37.